My research focuses on the dissection of growth signaling regulation in MDS and MDS/MPN and mechanisms implicated in the progression of chronic myeloid diseases to AML. My work incorporates gene editing by CRISPR-Cas9, signal transduction analysis, progenitor assays, drug screens and MDS/AML xenograft models.
Our lab studies the molecular biology of growth signaling regulation in MDS and MDS/MPN and investigates novel therapies that can effectively target these pathways using in vitro and in vivo models.
View all on PubMed
Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Sci Adv. 2022 Feb 18;8(7):eabl8952
Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. Haematologica. 2022 Dec 15
Karantanos T, Gondek LP, Varadhan R. Moliterno AR, Dezern AE, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with MDS/MPN. Br J Haematol. 2021 Jun;193(6):1142-1150
Karantanos T, Chaturvedi S, Braunstein EM, Spivak JL, Resar L, Karanika S, Williams D, Rogers O, Gocke C, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020 Jun 23;4(12):2567-2576
Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022 Aug;63(8):1942-1948